Document Preview
Management Plan:
Asthma is common and non-communicable and affects approximately 235 million people worldwide (Papi et al., 2020). It is characterized by episodic or persistent respiratory symptoms including wheezing, chest tightness, cough, and shortness of breath due to airflow limitation (Papi et al., 2020).
Diagnostic Tests: Asthma has no gold standard for diagnosing and can be challenging to diagnose (Saglani & Menzie-Gow, 2019). PFT tests for larger airway function include assessing FEV1 and forced vital capacity, but asthma often includes smaller airway dysfunction, specifically the outer airway walls of these smaller airways which are more difficult to test (Saglani & Menzie-Gow, 2019).
This being said spirometry is preferred diagnostic to determine a diagnosis of asthma (Global Initiative of Asthma, 2020).
Medications:
As per GINA guidelines adolescents with asthma should an as-needed low dose ICS-formoterol or regular lose dose ICS, plus as-needed SABA. (Global Initiative for Asthma, 2020).
Rx: budesonide/formoterol inhaled, (160mcg/4.5mcg per actuation) 2 puffs inhaled BID. Max 640 mcg/18mcg/day. Issue: 1 Refill: 1
Rx: ProAir HFA (inhaled albuterol) [1 actuation = 108 mcg albuterol sulfate equivalent to 90 mcg albuterol base] 2 puffs inhaled q4-6h PRN for exacerbation. Issue: 1 Refill: 1
RX: Singulair (Montelukast) 10mg by mouth daily in evening to help with allergy associated symptoms.
Issue: 30 pills Refill: 1……….. Continue
Instituition / Term | |
Term | Spring Session |
Institution | Chamberlain |
Contributor | Christie |